Arthur L. Corbin

Array ( [id] => 16948402 [patent_doc_number] => 20210207093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE [patent_app_type] => utility [patent_app_number] => 17/189243 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17189243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18351332 [patent_doc_number] => 20230139443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => TREATING AUTOSOMAL DOMINANT BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME [patent_app_type] => utility [patent_app_number] => 17/904899 [patent_app_country] => US [patent_app_date] => 2021-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308668 [patent_doc_number] => 20230112568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => TREATING AUTOSOMAL RECESSIVE BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME [patent_app_type] => utility [patent_app_number] => 17/904903 [patent_app_country] => US [patent_app_date] => 2021-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18310405 [patent_doc_number] => 20230114305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => RECOMBINANT MYXOMA VIRUSES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/801206 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18250968 [patent_doc_number] => 20230078007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => IN-SERIES SYNTHETIC RECEPTOR AND-GATE CIRCUITS FOR EXPRESSION OF A THERAPEUTIC PAYLOAD BY ENGINEERED CELLS [patent_app_type] => utility [patent_app_number] => 17/800872 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18177750 [patent_doc_number] => 20230038479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => GENE THERAPY [patent_app_type] => utility [patent_app_number] => 17/791169 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18225083 [patent_doc_number] => 20230064077 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => TREATMENT OF MUCOPOLYSACCHARIDOSIS IVA [patent_app_type] => utility [patent_app_number] => 17/792969 [patent_app_country] => US [patent_app_date] => 2021-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -115 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17768251 [patent_doc_number] => 11400170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Methods for treating cancers [patent_app_type] => utility [patent_app_number] => 17/157790 [patent_app_country] => US [patent_app_date] => 2021-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 71 [patent_no_of_words] => 39546 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18227591 [patent_doc_number] => 20230066585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES [patent_app_type] => utility [patent_app_number] => 17/789729 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17789729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806198 [patent_doc_number] => 20210128751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/143019 [patent_app_country] => US [patent_app_date] => 2021-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17143019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17080560 [patent_doc_number] => 20210275566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => COMPOSITIONS FOR CONFERRING TOLERANCE TO VIRAL DISEASE IN SOCIAL INSECTS, AND THE USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/134483 [patent_app_country] => US [patent_app_date] => 2020-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15491 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17134483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910534 [patent_doc_number] => 11873505 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Compositions and methods for regulating production of a precursor protein [patent_app_type] => utility [patent_app_number] => 17/132385 [patent_app_country] => US [patent_app_date] => 2020-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6045 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17132385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228633 [patent_doc_number] => 20210355189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => HIGH AFFINITY MAGE-A1-SPECIFIC TCRS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/131688 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17131688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20526042 [patent_doc_number] => 12544461 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Isolated nucleic acid molecule and application thereof [patent_app_type] => utility [patent_app_number] => 17/788713 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 4142 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18183490 [patent_doc_number] => 20230044220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => TREATMENT OF CHRONIC PAIN [patent_app_type] => utility [patent_app_number] => 17/786643 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18208311 [patent_doc_number] => 20230054569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA [patent_app_type] => utility [patent_app_number] => 17/786849 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612662 [patent_doc_number] => 20230279394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES [patent_app_type] => utility [patent_app_number] => 17/786347 [patent_app_country] => US [patent_app_date] => 2020-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 108389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -83 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870411 [patent_doc_number] => 20210163878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => MODULATION OF TISSUE FATTY ACID COMPOSITION OF A HOST BY HUMAN GUT BACTERIA [patent_app_type] => utility [patent_app_number] => 17/120743 [patent_app_country] => US [patent_app_date] => 2020-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17120743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18208883 [patent_doc_number] => 20230055143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 [patent_app_type] => utility [patent_app_number] => 17/783463 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16901115 [patent_doc_number] => 20210180031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => RECOMBINANT AAVS HAVING USEFUL TRANSCYTOSIS PROPERTIES [patent_app_type] => utility [patent_app_number] => 17/116168 [patent_app_country] => US [patent_app_date] => 2020-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17116168 [rel_patent_id] =>[rel_patent_doc_number] =>)